Journal of Affective Disorders
Volume 85, Issue 3 , Pages 245-258 , April 2005

Agitated “unipolar” depression re-conceptualized as a depressive mixed state: implications for the antidepressant-suicide controversy

  • Hagop S. Akiskal

      Affiliations

    • Department of Psychiatry and International Mood Center, University of California, La Jolla, CA, USA
    • ,
  • Franco Benazzi

      Affiliations

    • Hecker Psychiatry Research Center, Ravenna, Italy
    • Department of Psychiatry, National Health Service, Forli, Italy
    • Corresponding Author InformationCorresponding author. Via Pozzetto 17, 48010 Castiglione di Cervia RA, Italy. Tel.: +39 335 6191 852; fax: +39 054 330 069.
    • ,
  • Giulio Perugi

      Affiliations

    • Department of Psychiatry, University of Pisa, Pisa, Italy
    • ,
  • Zoltán Rihmer

      Affiliations

    • National Institute for Psychiatry and Neurology, Budapest, Hungary

Received 4 October 2004 ,Accepted 14 December 2004.

References 

  1. Akiskal HS. Developmental pathways to bipolarity: are juvenile-onset depressions pre-bipolar?. J. Am. Acad. Child Adolesc. Psych. 1995;34:754–763
  2. Akiskal HS. Validating “hard” and “soft” phenotypes within the bipolar spectrum: continuity or discontinuity?. J. Affect. Disord. 2003;73:1–5
  3. Akiskal HS, Benazzi F. Family history validation of the bipolar nature of depressive mixed states. J. Affect. Disord. 2003;73:113–122
  4. Akiskal HS, Benazzi F. Validating Kraepelin's two types of depressive mixed states: “depression with flight of ideas” and “excited depression”. World J. Biol. Psychiatry. 2004;5:107–113
  5. Akiskal HS, Benazzi F. Psychopathologic correlates of suicidal ideation in major depressive outpatients: is it all due to unrecognized bipolar depressive mixed states?. Psychopathology. 2005;(in press)
  6. Akiskal HS, Mallya G. Criteria for the “soft” bipolar spectrum: treatment implications. Psychopharmacol. Bull. 1987;23:68–73
  7. Akiskal HS, Pinto O. The evolving bipolar spectrum: prototypes I, II, III, and IV. In:  Akiskal HS editors. Bipolarity: beyond classic mania. Psychiatr. Clin. North Am. vol. 22:1999;p. 517–534
  8. Akiskal HS, Djenderedjian AH, Rosenthal RH, Khani MK. Cyclothymic disorder: validating criteria for inclusion in the bipolar affective group. Am. J. Psychiatry. 1977;134:1227–1233
  9. Akiskal HS, Bitar AH, Puzantian VR, Rosenthal TL, Walker PW. The nosological status of neurotic depression: a prospective three-to-four year examination in light of the primary–secondary and unipolar–bipolar dichotomies. Arch. Gen. Psychiatry. 1978;35:756–766
  10. Akiskal HS, Bourgeois ML, Angst J, Post R, Moller H-J, Hirschfeld R. Re-evaluating the prevalence and diagnostic composition within the broad clinical spectrum of bipolar disorders. J. Affect. Disord. 2000;59(Suppl. 1):S5–S30
  11. Altshuler LL, Post RM, Leverich GS, Mikalauskas K, Rosoff A, Ackerman L. Antidepressant-induced mania and cycle acceleration: a controversy revisited. Am. J. Psychiatry. 1995;152:1130–1138
  12. American Psychiatric Association . Diagnostic and statistical manual of mental disorders. Text revision (DSM-IV-TR). 4th ed.. Washington, DC: American Psychiatric Association; 2000;
  13. Andreasen NC, Grove WM. The classification of depression: traditional versus mathematical approaches. Am. J. Psychiatry. 1982;139:45–52
  14. Angst J, Angst F, Stassen HH. Suicide risk in patients with major depressive disorder. J. Clin. Psychiatry. 1999;60(Suppl. 2):57–62
  15. Angst F, Stassen HH, Clayton PJ, Angst J. Mortality of patients with mood disorders: follow-up over 34–38 years. J. Affect. Disord. 2002;68:167–181
  16. Baldessarini RJ, Tondo L, Hennen J. Lithium treatment and suicide risk in major affective disorders: update and new findings. J. Clin. Psychiatry. 2003;64(Suppl. 5):44–52
  17. Barbui C, Campomani A, D'Avanzo B, Negri E, Gorattini S. Antidepressant drug use in Italy since the introduction of the SSRI's: national trends, regional differences and impact on suicide rates. Soc. Psychiatr. Psychiatr. Epidemiol. 1999;34:152–156
  18. Bauer M, Bschor T, Kunz D, Berghöfer A, Ströhle A, Müller-Oerlinghausen B. Double-blind placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. Am. J. Psychiatry. 2000;157:1429–1435
  19. Beasley CM, Dornseif BE, Bosomworth JC, Sayler ME, Rampsey AH, Heiligenstein JH, et al. Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. Br. Med. J. 1991;303:685–692
  20. Beasley CM, Koke SC, Nilsson ME, Gonzales JS. Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysis. Clin. Ther. 2000;22:1319–1330
  21. Benazzi F. Borderline personality disorder and bipolar II disorder in private practice depressed outpatients. Compr. Psychiatry. 2000;41:106–110
  22. Benazzi F. Which could be a clinically useful definition of depressive mixed state?. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2002;26:1105–1111
  23. Benazzi F. Depression with racing thoughts. Psychiatry Res. 2003;120:273–282
  24. Benazzi F, Akiskal HS. Refining the evaluation of bipolar II: beyond the strict SCID-CV guidelines for hypomania. J. Affect. Disord. 2003;73:33–38
  25. Benazzi F, Helmi S, Bland L. Agitated depression: unipolar? bipolar? or both?. Ann Clin. Psychiatry. 2002;14:97–104
  26. Bertolote JM. Suicide prevention: at what level does it work?. World Psychiatry. 2004;3:147–151
  27. Bottlender R, Rudolf D, Strauss A, Möller H-J. Mood-stabilizers reduce the risk of developing antidepressant-induced maniform states in acute treatment of bipolar I depressed patients. J. Affect. Disord. 2001;63:79–83
  28. Bottlender R, Sato T, Kleindienst N, Strausz A, Moller H-J. Mixed depressive features predict maniform switch during treatment of depression in bipolar I disorder. J. Affect. Disord. 2004;78:149–152
  29. Brown RP, Sweeney J, Loutsch E, Kocsis J, Frances A. Involutional melancholia revisited. Am. J. Psychiatry. 1984;141:24–28
  30. Brugha TS, Jenkins R, Taub N, Meltzer H, Bebbington PE. A general population comparison of the Composite International Diagnostic Interview (CIDI) and the Schedules for Clinical Assessment in Neuropsychiatry (SCAN). Psychol. Med. 2001;31:1001–1013
  31. Busch KA, Fawcett J, Jacobs DG. Clinical correlates of inpatient suicide. J. Clin. Psychiatry. 2003;64:14–19
  32. Caligiuri MP, Gentili V, Eberson S, Kelsoe J, Rapoport M, Gillin JC. A quantitative neuromotor predictor of antidepressant non-response in patients with major depression. J. Affect. Disord. 2003;77:135–141
  33. Coryell W. Bipolar II disorder: the importance of hypomania. In:  Goldberg JF,  Harrow M editor. Bipolar disorders. Clinical course and outcome. Washington, DC: American Psychiatric Press; 1999;p. 219–236
  34. Culpepper L, Davidson JRT, Dietrich AJM, Goodman WK, Kroenke K, Schwenk TL. Suicidality as a possible side effect of antidepressant treatment. J. Clin. Psychiatry. 2004;65:742–749
  35. Davidson JR, Woodbury MA, Zisook S, Giller EL. Classification of depression by grade of membership: a confirmation study. Psychol. Med. 1989;19:987–998
  36. Delini-Stula A, Mikkelsen H, Angst J. Therapeutic efficacy of antidepressants in agitated anxious depression—a meta-analysis of moclobemide studies. J. Affect. Disord. 1995;35:21–30
  37. Dunner DL. Clinical consequences of under-recognized bipolar spectrum disorder. Bipolar Disord. 2003;5:456–464
  38. Dunner DL, Tay KL. Diagnostic reliability of the history of hypomania in bipolar II patients and patients with major depression. Compr. Psychiatry. 1993;34:303–307
  39. Fava M, Rosenbaum JF, Hoog SL, Tepner RG, Koop JB, Nilsson ME. Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression. J. Affect. Disord. 2000;59:119–126
  40. Faedda GL, Baldessarini RJ, Glovinsky IP, Austin NB. Treatment-emergent mania in pediatric bipolar disorder: a retrospective case review. J. Affect. Disord. 2004;82:149–158
  41. FDA: http://www.fda.gov/cder/drug/antidepressants/default.htm (accessed 29 November 2004).
  42. Filteau MJ, Baruch P, Lapierre YD, Bakish D, Blanchard A. SSRIs in anxious-agitated depression: a post-hoc analysis of 279 patients. Int. Clin. Psychopharmacol. 1995;10:51–54
  43. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured clinical interview for DSM-IV axis I disorders-clinician version (SCID-CV). Washington, DC: American Psychiatric Press; 1997;
  44. Garvey MJ, Schaffer CB. Are some symptoms of depression age dependent?. J. Affect. Disord. 1994;32:247–251
  45. Ghaemi SN, Rosenquist KL, Ko JY, Baldassano CF, Kontos NJ, Ross J, et al. Antidepressant treatment in bipolar versus unipolar depression. Am. J. Psychiatry. 2004;161:163–165
  46. Goldberg JF, Truman CJ. Antidepressant-induced mania: an overview of current controversies. Bipolar Disord. 2003;5:407–420
  47. Goldney RG, Dal Grande E, Fisher LJ, Wilson D. Population attributable risk of major depression for suicidal ideation in a random and representative community sample. J. Affect. Disord. 2003;74:267–272
  48. Gunnell D, Harbord R, Singleton N, Jenkins R, Lewis G. Factors influencing the development and amelioration of suicidal thoughts in the general population. Cohort study. Br. J. Psychiatry. 2004;185:385–393
  49. Hall WD, Mant A, Mitchell PB, Rendle VA, Hickie IB, McManus P. Association between antidepressant prescribing and suicide in Australia, 1991–2000: trend analysis. Br. Med. J. 2003;326:1008–1012
  50. Hantouche EG, Akiskal HS, Lancrenon S, Chatenêt-Duchêne L. Mood stabilizer augmentation in apparently “unipolar” MDD: predictors of response in the naturalistic French national EPIDEP study. J. Affect Disord. 2005;(in press)
  51. Haykal R, Akiskal HS. The long-term outcome of dysthymia in private practice: clinical features, temperament, and the art of management. J. Clin. Psychiatry. 1999;60:508–518
  52. Healy D. Lines of evidence on the risk of suicide with selective serotonine reuptake inhibitors. Psychother. Psychosom. 2003;72:71–79
  53. Helgason T, Tómasson H, Zoéga T. Antidepressants and public health in Iceland. Time series analysis of national data. Br. J. Psychiatry. 2004;184:157–162
  54. Hirschfeld RMA, Calabrese JR, Weissman MM, Reed M, Davies MA, Frye MA, et al. Screening for bipolar disorder in the community. J. Clin. Psychiatry. 2003;64:53–59
  55. Isacsson G. Suicide prevention—a medical breakthrough?. Acta Psychiatr. Scand. 2000;102:113–117
  56. Kahn A, Warner HA, Brown WA. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials. An analysis of the food and drug administration database. Arch. Gen. Psychiatry. 2000;57:311–317
  57. Kahn A, Kahn SR, Leventhal RM, Brown WA. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: a replication analysis of the food and drug administration database. Int. J. Neuropsychopharmacol. 2001;4:113–118
  58. Kahn A, Kahn S, Kolts R, Brown WA. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. Am. J. Psychiatry. 2003;160:790–792
  59. Kelly CB, Ansari T, Rafferty T, Stevenson M. Antidepressant prescribing and suicide rate in Northern Ireland. Eur. Psychiatry. 2003;18:325–328
  60. Kendler KS, Eaves LJ, Walters EE, Neale MC, Heath AC, Kessler RC. The identification and validation of distinct depressive syndromes in a population-based sample of female twins. Arch. Gen. Psychiatry. 1996;53:391–399
  61. Kessler RC. Comorbidity of unipolar and bipolar depression with other psychiatric disorders in a general population survey. In:  Tohen M editors. Comorbidity in affective disorders. New York: Marcel Dekker; 1999;p. 1–25
  62. Kessler RC, Borges G, Walters EE. Prevalence and risk factors for lifetime suicide attempts in the National Comorbidity Survey. Arch. Gen. Psychiatry. 1999;56:617–626
  63. Khuri R, Akiskal HS. Suicide prevention: the necessity of treating contributory psychiatric disorders. Psychiatr. Clin. North Am. 1983;6:193–207
  64. Korszun A, Moskvina V, Brewster S, Craddock N, Ferrero F, Gill M, et al. Familiality of symptom dimensions in depression. Arch. Gen. Psychiatry. 2004;61:468–474
  65. Koukopoulos A, Koukopoulos A. Agitated depression as a mixed state and the problem of melancholia. Psychiatr. Clin. North Am. 1999;22:547–564
  66. Koukopoulos A, Faedda G, Proietti R, D'Amico S, de Pisa E, Simonetto C. Mixed depressive syndrome. Encephale. 1992;18:19–21
  67. Krabbendam L, Myin-Germeys I, De Graaf R, Vollebergh W, Nolen WA, Iedema J, et al. Dimensions of depression, mania and psychosis in the general population. Psychol. Med. 2004;34:1–10
  68. Kraepelin, E., (1899, 1921 English translation). Manic-depressive insanity and paranoia. Livingstone E & S, Edinburg.
  69. Kupfer DJ, Pickar D, Himmelhoch JM, Detre TP. Are there two types of unipolar depression?. Arch. Gen. Psychiatry. 1975;32:866–871
  70. Kupfer DJ, Frank E, Grochocinski VJ, Cluss PA, Kouck PR, Stapf DA. Demographic and clinical characteristics of individuals in a bipolar disorder case registry. J. Clin. Psychiatry. 2002;63:120–125
  71. Maj M, Pirozzi R, Magliano L, Bartoli L. Agitated depression in bipolar I disorder: prevalence, phenomenology, and outcome. Am. J. Psychiatry. 2003;160:2134–2140
  72. Maris RW. Suicide. The Lancet. 2002;360:319–326
  73. Marneros A. Origin and development of concepts of bipolar mixed states. J. Affect. Disord. 2001;67:229–240
  74. Maser JD, Akiskal HS, Zeller P, Scheftner W, Mueller T, Endicott J, et al. Can temperament identify affectively ill patients who engage in lethal or near-lethal suicidal behavior? A 14-year prospective study. Suicide and Life-Threatening Behavior. 2002;32:10–32
  75. Montgomery SA, Dunner DL, Dunbar GC. Reduction of suicidal thoughts with paroxetine in comparison with reference antidepressants and placebo. Eur. Neuropsychopharmacol. 1995;5:5–13
  76. Olfson M, Shaffer D, Marcus SC, Greenberg T. Relationship between antidepressant medication treatment and suicide in adolescents. Arch. Gen. Psychiatry. 2003;60:978–982
  77. Parker G. Classifying depression: should paradigms lost be regained?. Am. J. Psychiatry. 2000;157:1195–1203
  78. Perugi G, Akiskal HS, Micheli C, Toni C, Madaro D. Clinical characterization of depressive mixed state in bipolar-I patients: Pisa–San Diego collaboration. J. Affect. Disord. 2001;67:105–114
  79. Raskin A, Schulterbrandt J, Reating N, McKeon JJ. Replication of factors of psychopathology in interview, ward behavior and self-report ratings of hospitalized depressives. J. Nerv. Ment. Dis. 1969;148:87–98
  80. Rihmer Z. Can better recognition and treatment of depression reduce suicide rates? A brief review. Eur. Psychiatry. 2001;16:406–409
  81. Rihmer Z. Do SSRIs increase the risk of suicide among depressives even if they are taking only placebo?. Psychother. Psychosom. 2003;72:357–358
  82. Rihmer Z. Decreasing national suicide rates—fact or fiction?. World J. Biol. Psychiatry. 2004;5:55–56
  83. Rihmer Z, Szádóczky E, Füredi J, Kiss K, Papp Z. Anxiety disorders comorbidity in bipolar I, bipolar II and unipolar major depression: results from a population-based study in Hungary. J. Affect. Disord. 2001;67:175–179
  84. Rihmer Z, Belső N, Kiss K. Strategies for suicide prevention. Curr. Opin. Psychiatry. 2002;15:83–87
  85. Robins E, Guze SB. Establishment of diagnostic validity in psychiatric illness: its application to schizophrenia. Am. J. Psychiatry. 1970;126:983–987
  86. Rosack, J., 2004. FDA issues controversial black box warning. APA Psychiatric News 39, November 5, pp. 1 and 48.
  87. Rouillon F, Serrurier D, Miller HD, Gerard M-J. Prophylactic efficacy of maprotiline on unipolar depression relapse. J. Clin. Psychiatry. 1991;52:423–431
  88. Rutz W, von Knorring L, Walinder J. Frequency of suicide on Gotland after systematic postgraduate education of general practitioners. Acta Psychiatr Scand. 1989;80:151–154
  89. Sato T, Bottlender R, Schroter A, Moller H-J. Frequency of manic symptoms during a depressive episode and unipolar ‘depressive mixed state’ as bipolar spectrum. Acta Psychiatr. Scand. 2003;107:268–274
  90. Schatzberg AF, Rothschild AJ. Psychotic (delusional) major depression: should it be included as a distinct syndrome in DSM-IV?. Am. J. Psychiatry. 1992;149:733–745
  91. Simpson SG, McMahon FJ, McInnis MG, MacKinnon DF, Edwin D, Folstein SE, et al. Diagnostic reliability of bipolar II diagnosis. Arch. Gen. Psychiatry. 2002;59:736–740
  92. Spitzer RL, Endicott J, Robins E. Research diagnostic criteria. Arch. Gen. Psychiatry. 1978;35:773–782
  93. Storosum JG, van Zwieten BJ, van den Brink W, Gersons BPR, Broekmans AW. Suicide risk in placebo-controlled studies of major depression. Am. J. Psychiatry. 2001;158:1271–1275
  94. Sullivan PF, Kessler RC, Kendler KS. Latent class analysis of lifetime depressive symptoms in the National Comorbidity Survey. Am. J. Psychiatry. 2002;155:1398–1406
  95. Sullivan PF, Prescott CA, Kednler KS. The subtypes of major depression in a twin registry. J. Affect. Disord. 2002;68:273–284
  96. Swann AC, Secunda SK, Katz MM, Croughan J, Bowden CL, Koslow SH, et al. Specificity of mixed affective states: clinical comparison of dysphoric mania and agitated depression. J. Affect. Disord. 1993;28:81–89
  97. Thies-Flechtner K, Müller-Oerlinghausen B, Seibert W, Walther A, Greil W. Effect of prophylactic treatment on suicide risk in patients with major affective disorders. Pharmacopsychiatry. 1996;29:103–107
  98. Tollefson GD, Greist JH, Jefferson JW, Heiligenstein JH, Sayler ME, Tollefson SL, et al. Is baseline agitation a relative contraindication for a selective serotonin reuptake inhibitor: a comparative trial of fluoxetine versus imipramine. J. Clin. Psychopharmacol. 1994;14:385–391
  99. Wehr TA, Goodwin FK. Rapid cycling in manic-depressives induced by tricyclic antidepressants. Arch. Gen. Psychiatry. 1979;36:555–559
  100. Weissman MM, Wickramaratne P, Adams P, Wolk S, Verdeli H, Olfson M. Brief screening for family psychiatric history. The family history screen. Arch. Gen. Psychiatry. 2000;57:675–682
  101. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. The Lancet. 2004;363:1341–1345
  102. Wilens TE, Biederman J, Kwon A, Chase R, Greenberg L, Mick E, et al. A systematic chart review of the nature of psychiatric adverse effects in children and adolescents treated with selective serotonin reuptake inhibitors. J. Child Adolesc. Psychopharmacol. 2003;13:143–152
  103. Williams, J.B.W., Terman, M., Link, M.J., Amira, L., Rosenthal, N.E., 1994. Hypomania interview guide (including hyperthymia). Current assessment version (HIGH-C). Clinical Assessment Tools Packet, Center for Environmental Therapeutics, Norwood, NJ.
  104. WHO . The ICD-10 classification of mental and behavioural disorders. Geneva: World Health Organization; 1992;
  105. Yerevanian BI, Koek RJ, Mintz J. Lithium, anticonvulsants and suicidal behavior in bipolar disorder. J. Affect. Disord. 2003;73:223–228

PII: S0165-0327(04)00434-3

doi: 10.1016/j.jad.2004.12.004

Journal of Affective Disorders
Volume 85, Issue 3 , Pages 245-258 , April 2005

Article Tools